Check the latest news re Abbott.... The Wall Street Transcript publishes investing in Pharmaceuticals Issues..... " Traversa's other pick: ``I have one name, although I believe it is still at an early stage. It is Abbott (NYSE: ABT - news), mostly because of the low valuation. Abbott does not have a major blockbuster to launch in the year 2000 and beyond, to my knowledge. But at this valuation, and with the flow of small products, including the generic cyclosporine in co-promotion with SangStat (Nasdaq: SANG - news), we think that starting from the second half of 2000, it could present an interesting opportunity.''